Reports Q2 revenue $1.3M vs. $0.1M last year. As of June 30, Inhibrx (INBX) had cash and cash equivalents of $186.6M vs. $216.5M as of March 31. The decrease in EPS was primarily related to the $2.0B gain recorded in connection with the completion of the 101 Transaction in Q2 of 2024, offset in both periods by operational losses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX: